Physician profile
Da David Jiang
NPI 1639556384
$64,837.39
in general payments reported to CMS, 2019-2025
23 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $939 · 2021: $159 · 2022: $11K · 2023: $5,820 · 2024: $7,082 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $36K · Travel and Lodging: $9,404 · Food and Beverage: $6,245 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $36,043.02 |
| Travel and Lodging | $9,403.71 |
| Food and Beverage | $6,245.40 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $58,897.65 | 2019-2025 | Da Vinci Surgical System |
| Angiodynamics, INC. | $2,248.56 | 2023-2025 | Nanoknife |
| Procept Biorobotics Corporation | $1,155.44 | 2023 | Aquabeam Robotic System |
| Coloplast Corp | $526.16 | 2022 | |
| Sumitomo Pharma America, INC. | $411.21 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $326.14 | 2021-2024 | Myrbetriq, Veozah |
| Abbvie INC. | $261.18 | 2023-2025 | |
| Tolmar, INC. | $203.95 | 2023-2025 | Eligard, Jatenzo |
| Profound Medical Corp. | $171.41 | 2021-2022 | |
| Boston Scientific Corporation | $169.88 | 2024-2025 | Rezum Generator, Axonics |
| Pfizer INC. | $112.68 | 2023-2025 | |
| Progenics Pharmaceuticals, INC. | $80.86 | 2024-2025 | |
| Teleflex LLC | $63.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Laborie Medical Technologies Corp. | $26.18 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $24.86 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.49 | 2025 | Adstiladrin |
| Olympus America INC. | $22.25 | 2025 | Itind System |
| Accord Healthcare, INC. | $21.63 | 2024 | |
| Baxter Healthcare | $18.27 | 2023 | Tisseel |
| Urovant Sciences INC | $16.00 | 2022 | |
| Endo Pharmaceuticals INC. | $13.06 | 2022 | |
| Travere Therapeutics, INC. | $7.64 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Da David Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.